Biopta has been providing contract research services to the pharmaceutical industry since 2002 and has established itself as the world leader in the use of fresh functional human tissues to better predict drug activity prior to clinical trials. Biopta’s expertise in all areas of human tissues research including sourcing, handling and experimenting on human tissue allows us to act as your “Human Tissue Research Department”.
Biopta can help you reduce risk in drug development by providing early information based on fresh human tissue. The data that Biopta provides gives an accurate indication of human safety and efficacy, many years in advance of your compound reaching the clinical setting. This invaluable information allows you to make ‘go’ or ‘no-go’ decisions with certainty based on human data rather than with data from an animal model or cell culture which might be entirely irrelevant.
Biopta can help you increase speed to market because we have regular and frequent access to both healthy and diseased tissues allowing us to carry out comparison studies in different patient populations. The data we provide will enable you to streamline your ‘proof of concept’ studies saving both time and money. You can also test your drugs for efficacy in alternative indications using one or more of our human tissue assays. Our models are far more cost effective than setting up a clinical efficacy study which has no guarantee of success and in most cases our data can be available within weeks of study initiation.
Biopta can help you troubleshoot drug development. All too frequently, unwanted or adverse side effects are revealed in the clinic. Most timest these were never predicted in the animal models employed throughout pre-clinical development. At Biopta we can help you investigate these occurrences using human tissues. Alternatively, we can recommend human tissue assays that will help confirm the safety of your compound during discovery or non-clinical development. This data will allow you to modify or even halt your compounds before any expensive trials are undertaken.
Acquired by REPROCELL in 2015, Biopta was later merged with Reinnervate Company (County Durham, UK) to form the headquarters of REPROCELL Europe, located in Glasgow, Scotland, UK. In 2017, the REPROCELL European offices and labs moved to a new location. Named the Centre for Predictive Drug Discovery, the new facility has an expanded footprint and includes new labs and capabilities for 3D cell culture assays and induced pluripotent stem cell (iPSC) services. The Centre of Predictive Drug Discovery is a Good Laboratory Practice (GLP) certified facility. Available 24/7 to create data in freshly sourced human tissues, Biopta will add value and de-risk drug development programs by predicting the safety, efficacy, absorption or metabolism of compounds in phenotypically-relevant healthy and diseased human tissues.
Above: Centre for Predictive Drug Discovery laboratories in Glasgow, Scotland (UK)